Predicting the biologic behavior of ductal carcinoma in situ: An analysis of molecular markers

Hieken, Tina J.; Farolan, Miguel; D'Alessandro, Stephen Paul; Velasco, Josè M.

doi:10.1067/msy.2001.116921

Cited by 33 publications

(28 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results have been obtained in the study by Turner et al [18] In DCIS, there are not many studies that describe the relation between p53 immunoreactivity and LR. Two groups of investigators, however, have shown that p53 positive expression is also associated with LR in DCIS [19,20].…”

Section: Discussionmentioning

confidence: 99%

p53 Overexpression is a Predictor of Local Recurrence After Treatment for Both in situ and Invasive Ductal Carcinoma of the Breast

Roos

Bock

Vries

et al. 2007

Journal of Surgical Research

View full text Add to dashboard Cite

p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast de Roos, M.A.; de Bock, G.H.; de Vries, J; van der Vegt, Bert; Wesseling, J. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Background. Several biological markers have been related to prognosis in mammary ductal carcinoma. The aim of the study was to determine biological markers that could predict local recurrence following treatment for all stages of primary operable ductal carcinoma of the breast.Materials and methods. A consecutive series of patients treated for pure ductal carcinoma in situ (DCIS, n ‫؍‬ 110) and invasive ductal carcinoma (IDC, n ‫؍‬ 243) was studied. Twenty-three patients with DCIS were excluded because of lack of original paraffin embedded tissue. All patients had been treated between July 1996 and December 2001. Median follow-up was 49.8 mo. From the original paraffin embedded tumors, tissue microarrays (TMAs) were constructed. On these TMAs, immunohistochemistry was performed for estrogen-receptor (ER), progesterone-receptor (PR), Her2/neu, p53, and cyclin D1. Main outcome was the event of LR. All analyses were stratified for diagnosis (DCIS or IDC) and pathological grade.Results. In univariate analyses, Her2/neu overexpression (hazard ratio [HR] 3.1, 95% confidence interval [CI] 1.1-8.7, P ‫؍‬ 0.032) and p53 overexpression (HR 3.5, 95% CI 1.3-9.3, P ‫؍‬ 0.014) were associated with LR in patients treated for both DCIS and IDC. In multivariate analysis, p53 overexpression (HR 3.0, 95% CI 1.1-8.2, P ‫؍‬ 0.036 and HR 4.4, 95% CI 1.5-12.9, P ‫؍‬ 0.008) and adjuvant radiotherapy (HR 0.2, 95% CI 0.1-0.8, P ‫؍‬ 0.026) were independent common predictors of LR in patients who had received treatment for both DCIS and IDC.Conclusions. p53 overexpression is a common predictor of LR following treatment for all stages of primary operable ductal carcinoma of the breast. This marker may help in planning optimal treatment and follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

p53 Overexpression is a Predictor of Local Recurrence After Treatment for Both in situ and Invasive Ductal Carcinoma of the Breast

Roos

Bock

Vries

et al. 2007

Journal of Surgical Research

View full text Add to dashboard Cite

show abstract

“…For example, mutant p53 has been found in ductal carcinoma in situ (DCIS), a human premalignant breast lesion. 30,31 In liver cancer, TP53 is thought to be eliminated along with the RB and C/ EBPα tumor suppressors following elevation of gankyrin at early stages of M Monographs tumorigenesis.…”

Section: Occurrence Of P53 Mutations At Early Phases Of the Tumorigenmentioning

confidence: 99%

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

Rivlin

Brosh²,

Oren³

et al. 2011

Genes & Cancer

820

586

View full text Add to dashboard Cite

Inactivation of the p53 tumor suppressor is a frequent event in tumorigenesis. In most cases, the p53 gene is mutated, giving rise to a stable mutant protein whose accumulation is regarded as a hallmark of cancer cells. Mutant p53 proteins not only lose their tumor suppressive activities but often gain additional oncogenic functions that endow cells with growth and survival advantages. Interestingly, mutations in the p53 gene were shown to occur at different phases of the multistep process of malignant transformation, thus contributing differentially to tumor initiation, promotion, aggressiveness, and metastasis. Here, the authors review the different studies on the involvement of p53 inactivation at various stages of tumorigenesis and highlight the specific contribution of p53 mutations at each phase of cancer progression.

show abstract

“…Interestingly, no correlation was found between VEGF expression and the degree of vascularization in that study. On the other hand, Hieken TJ et al suggested that VEGF expression may help predict the biologic aggressiveness of DCIS (Hieken et al 2001). Additionally, in the context of DCIS, Vogl et al provide evidence to support the idea that VEGF expression is not regulated by the HER2 pathway (Vogl et al 2005).…”

Section: Vascular Endothelial Growth Factor (Vegf) and Angiogenesismentioning

confidence: 79%

Intraepithelial Neoplasia of Breast

Monti¹,

Castillo²

2012

Intraepithelial Neoplasia

View full text Add to dashboard Cite

Predicting the biologic behavior of ductal carcinoma in situ: An analysis of molecular markers

Cited by 33 publications

References 18 publications

p53 Overexpression is a Predictor of Local Recurrence After Treatment for Both in situ and Invasive Ductal Carcinoma of the Breast

p53 Overexpression is a Predictor of Local Recurrence After Treatment for Both in situ and Invasive Ductal Carcinoma of the Breast

Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis

Intraepithelial Neoplasia of Breast

Contact Info

Product

Resources

About